The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Open accessAbstract
The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein–DNA interactions. Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small molecule inhibitors of the BET family of chromatin adaptors. MYC transcriptional suppression was observed in the context of the natural, chromosomally translocated, and amplified gene locus. Inhibition of BET bromodomain–promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G 1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors. MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor. Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. These findings demonstrate that pharmacologic inhibition of MYC is achievable through targeting BET bromodomains. Such inhibitors may have clinical utility given the widespread pathogenetic role of MYC in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 5×
“BET inhibitors exhibit anticancer effects in both in vitro and in vivo models of midline carcinoma (8), a rare but lethal disease that frequently harbors a chromosomal translocation in which the bromodomains of BRD4 are fused to the NUT gene (9).”
BackgroundResultInfluentialSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Elongation by RNA polymerase II: the short and long of it
Sims, R. J., Belotserkovskaya, R., & Reinberg, D. (2004) · Genes & Development · doi:10.1101/gad.1235904 · Cited by 709
Self-citationSeoane, J., Le, H.-V., & Massagué, J. (2002) · Nature · doi:10.1038/nature01119 · Cited by 684
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
Wu, S.-Y., & Chiang, C.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700001200 · Cited by 679
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Translocations involving c-myc and c-myc function
Boxer, L. M., & Dang, C. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204595 · Cited by 479
The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
LeRoy, G., Rickards, B., & Flint, S. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.01.018 · Cited by 372
Yang, Z., He, N., & Zhou, Q. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01020-07 · Cited by 347
Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
Dey, A., Nishiyama, A., Karpova, T., McNally, J., & Ozato, K. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-05-0380 · Cited by 316
Negative Regulation of the Mammalian UV Response by Myc through Association with Miz-1
Herold, S., Wanzel, M., Beuger, V., Frohme, C., Beul, D., Hillukkala, T., Syvaoja, J., Saluz, H.-P., Haenel, F., & Eilers, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00633-0 · Cited by 307
MYC in Oncogenesis and as a Target for Cancer Therapies
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07006-5 · Cited by 242
French, C. A. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.06.007 · Cited by 187
MYC regulation of a “poor-prognosis” metastatic cancer cell state
Wolfer, A., Wittner, B. S., Irimia, D., Flavin, R. J., Lupien, M., Gunawardane, R. N., Meyer, C. A., Lightcap, E. S., Tamayo, P., Mesirov, J. P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914203107 · Cited by 177
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
Dib, A., Gabrea, A., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn011 · Cited by 131
Lapalombella, R., Zhao, X. B., Triantafillou, G., Yu, B., Jin, Y., Lozanski, G., Cheney, C. M., Heerema, N. A., Jarjoura, D. G., Lehman, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1006 · Cited by 32
Cited by
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Finally, primaryoracquiredresistancecanalsoarisebyactivationofheterologous pathwaysleadingtocommonendpoints;forinstance,MYC-dependent transcriptional activation or ERK activity (in pink, ‘‘4’’). mTORC2 and PDK1 and shares with AKT the ability to phosphorylate TSC2, leading to mTORC1 activation.”
InfluentialPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Metadata
- Authors
- Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-09-26
- Volume
- 108
- Issue
- 40
- Pages
- 16669-16674
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2009949436
- Cited by
- 1,110
- References
- 22
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.